Orencia (abatacept)

P3, N=400, Recruiting, Duke University | Not yet recruiting --> Recruiting

P2, N=160, Recruiting, Boston Children's Hospital | Active, not recruiting --> Recruiting

P=N/A, N=72, Recruiting, Hospital for Special Surgery, New York | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=20, Not yet recruiting, National Cancer Institute (NCI)

P2, N=27, Active, not recruiting, NYU Langone Health | Trial completion date: Aug 2026 --> Jan 2027 | Trial primary completion date: Aug 2025 --> Jan 2027

P2/3, N=64, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

We aimed to analyse incident malignancies under treatment with JAKi, tumour necrosis factor inhibitors (TNFi), abatacept (ABA), rituximab (RTX), interleukin 6 inhibitors (IL6i) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs - bionaive) in patients with rheumatoid arthritis (RA) observed in daily rheumatological care. IR of malignancies in selected patients receiving JAKi in a real-world setting was numerically higher than the IR reported for tofacitinib in the Oral Surveillance study. However, we found no statistical evidence of an increased risk of malignancies with JAKi compared to TNFi, although patients on JAKi were older and had longer disease duration and more previous b/tsDMARDs treatments. Further analyses assessing exposure in terms of treatment duration are needed.

Case Report A 69 -yo f with a PMH of type 2 DM, hypertension, obstructive sleep apnea, high-grade PT3NO urothelial cancer with status post-cystectomy, and two cycles of ICI with nivolumab presented to the clinic 11 days following her second dose of chemotherapy with nivolumab with symptoms of dyspnea...Myocardial biopsy results showed interstitial lymphocyte infiltrates with myocardial injury confirming the suspected diagnosisGoal-directed medical therapy was initiated for heart failure with a newly reduced ejection fraction with IV lasix, hydralazine, and isosorbide dinitrate...Even though evidence guiding treatment of ICI-induced myocarditis is not evidence-based, inflammatory responses of a higher grade on endomyocardial biopsy should prompt intensification of immunosuppression with regimens like mycophenolate mofetil,abatacept or alemtuzumab (11-13) in addition to high-dose steroids...This case described the diagnostic approach and management of ICI-induced myocarditis with third-degree heart block and cardiogenic shock. Initial workup with cardiac biomarkers, ECG, TTE, and myocardial biopsy during right heart catheterization was critical in treatment decision-making and ruling out other potential causes.

P2, N=15, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Apr 2023 --> Jul 2023

P2, N=186, Active, not recruiting, Boston Children's Hospital | Trial completion date: Feb 2023 --> Sep 2023

She was trialed on Cellcept followed by IVIg with limited response. PID should be suspected in Pediatric Evans syndrome in patients with refractory disease, multiorgan autoimmunity, and/or positive family history for autoimmunity. Furthermore, the diagnosis of CTLA4 haploinsufficiency allows for targeted therapy with abatacept which may have beneficial effects on autoimmune cytopenias and enteropathy.

Thirteen pts received TBI-based myeloablative preparative regimen, 15 treosulfan-based with either cyclophosphamide (n=20) or thiotepa (n=1) or vepesid (n=7) as a second agent...Transplant-related mortality was 4 % (95% CI: 0,06-29): one pt with ALL previously receiving inotuzumab ozogamicin, died in CR due to severe VOD on day + 60... Preliminary data suggest that addition of vedolizumab and abatacept to the PtCy-based GVHD prophylaxis is not associated with increased toxicity and may reduce the incidence of gut GVHD. This approach can be further tested in a prospective trial with the goal to increase the anti-leukemic efficacy of HSCT.